Estimulação direcionada a biomarcadores para eventos epileptiformes (BTSEE)
Segurança e eficácia da estimulação direcionada por biomarcadores na epilepsia
This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: David Himes, BSEE
- Número de telefone: 425-679-9505
- E-mail: dhimes@cadenceneuro.com
Locais de estudo
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Recrutamento
- Lucile Packard Children's Hospital Stanford
-
Contato:
- Swetapadma Patnaik
- Número de telefone: (650) 721-1458
- E-mail: sweta@stanford.edu
-
Investigador principal:
- Ann Hyslop Segeren, MD
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Recrutamento
- Mayo Clinic
-
Contato:
- Karla Crockett
- Número de telefone: 507-538-9140
- E-mail: Crockett.Karla@mayo.edu
-
Investigador principal:
- Nicholas Gregg, MD
-
-
Texas
-
Fort Worth, Texas, Estados Unidos, 76104
- Recrutamento
- Cook Children's Medical Center
-
Contato:
- Mariana Gallardo
- Número de telefone: 682-303-4916
- E-mail: Mariana.Gallardo@cookchildrens.org
-
Investigador principal:
- M. Scott Perry, MD
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Recrutamento
- Seattle Children's Hospital
-
Investigador principal:
- Hannah Goldstein, MD
-
Contato:
- Deborah Grenard
- Número de telefone: 206-987-8078
- E-mail: Cadence@seattlechildrens.org
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subject is greater than or equal to 7 years of age.
- Subject has focal onset seizures.
- Subject has failed treatment with a minimum of two AED's used in typical therapeutic dosages.
- Subject has seizures that are distinct, stereotypical events that can be reliably counted by the patient or caregiver.
- Subject can reasonably be expected to maintain a seizure diary and the BTS System alone, or with the assistance of a competent individual.
- For one month prior to enrollment, subject's anti-epileptic medication dosages and ketogenic diet (as applicable) have been stable (other than acute, intermittent use of benzodiazepines) and subject has had at least three primary, disabling seizures per month, on average. Seizures must be separated by a minimum of eight hours not to be considered part of a cluster. A cluster, for the purpose of this criterion, shall be considered a single seizure.
- Subject is able to complete regular office visits and telephone appointments in accordance with the study protocol requirements.
- A female subject of childbearing age must have a negative serum pregnancy test within two weeks prior to implant of the INSR, and, if sexually active, must be using a reliable form of birth control, be surgically sterile, or be at least two years post-menopausal.
- Subject has been informed of their eligibility for resective surgery as a potential alternative to the study, if such surgery is a reasonable option.
- Subject has had a brain MRI epilepsy evaluation within the past two years.
- Subject's anatomy will permit implantation of the INSR within 20 mm of the skin surface.
Exclusion Criteria:
-
Subject has a history of substance abuse within the preceding two years.
-
Subject participated in another drug or device trial that may confound study results within the preceding 30 days.
-
Subject is implanted with pacemaker, implantable cardiac defibrillator, cardiac management product, or a medical device that interferes with the BTS System or with which the BTS System interferes. Patients with a vagus nerve stimulator (VNS) implanted may be enrolled, provided their VNS remains off while the BTS System is implanted.
-
Subject has anatomy that may interfere with electrode placement.
-
Subject is on anticoagulants and is unable to discontinue them perisurgically, as required by the neurosurgeon or Investigator.
-
Subject has significant platelet dysfunction from medical conditions or medications (including, particularly, aspirin or sodium valproate). If platelet dysfunction is suspected, subject can be enrolled only if a hematologist, the Investigator, and the neurosurgeon judge it to be advisable.
-
Subject has been diagnosed with psychogenic or non-epileptic seizures that cannot be distinguished from their epileptogenic events.
-
Subject is ineligible for cranial surgery or has medical and/or neurologically unstable condition (e.g brain tumor, multiple sclerosis, dementia, or intracranial vascular lesion).
-
Subject has been diagnosed with active psychosis, major depression, or suicidal ideation in the preceding 6 months.
-
Subject has primary generalized seizures.
-
Subject has experienced unprovoked convulsive status epilepticus in the preceding year, defined as:
- The active part of a tonic-clonic seizure lasts 5 minutes or longer, or
- Repeated tonic-clonic seizures without recovering consciousness for a period of longer than 5 minutes
-
Subject, in the opinion of the Investigator, would be a poor study candidate.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Tratamento
|
Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse event rate
Prazo: Intervals through 7, 12, and 24 months post-implant
|
Determine adverse event rate, including adverse device effects and serious adverse events |
Intervals through 7, 12, and 24 months post-implant
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Seizure frequency
Prazo: Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
Using seizure diaries, calculate disabling seizure frequency, normalized to months, compared to baseline. |
Intervals calculated at 4 to 7 months and through 12 and 24 months post-implant.
|
|
Neurocognitive testing
Prazo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Neurocognitive tests, using the NIH Toolbox, including the Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Depression testing
Prazo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported depression evaluation using Child Depression Inventory (CDI) or Beck Depression Inventory (BDI) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Anxiety testing
Prazo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported anxiety evaluation using Revised Children's Manifest Anxiety Scale (RCMAS-2) or Beck Anxiety Inventory (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Quality of life testing
Prazo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported quality of life evaluation using Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55), Quality of Life in Epilepsy Inventory for Adolescents (QOLIE-AD-48), or Quality of Life in Epilepsy (QOLIE-31) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Sleep testing
Prazo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported sleep evaluation using Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) or Epworth Sleepiness Scale (ESS) (depending on age), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Seizure severity testing
Prazo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Patient reported seizure severity evaluation using Liverpool Seizure Severity Scale 2.0 (LSSS 2.0), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Caregiver burden testing
Prazo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Caregiver reported burden evaluation using Caregiver Burden Inventory (CBI), compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
|
Suicidality risk testing
Prazo: Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Tool used to assess the severity and immediacy of suicide risk through a series of plain-language questions, compared to baseline. |
Evaluated at 7 months, 12 months, and 24 months post-implant.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicações e links úteis
Publicações Gerais
- Lundstrom BN, Worrell GA, Stead M, Van Gompel JJ. Chronic subthreshold cortical stimulation: a therapeutic and potentially restorative therapy for focal epilepsy. Expert Rev Neurother. 2017 Jul;17(7):661-666. doi: 10.1080/14737175.2017.1331129. Epub 2017 May 25.
- Kerezoudis P, Grewal SS, Stead M, Lundstrom BN, Britton JW, Shin C, Cascino GD, Brinkmann BH, Worrell GA, Van Gompel JJ. Chronic subthreshold cortical stimulation for adult drug-resistant focal epilepsy: safety, feasibility, and technique. J Neurosurg. 2018 Aug;129(2):533-543. doi: 10.3171/2017.5.JNS163134. Epub 2017 Oct 20.
- Lundstrom BN, Gompel JV, Khadjevand F, Worrell G, Stead M. Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy. Brain Commun. 2019;1(1):fcz010. doi: 10.1093/braincomms/fcz010. Epub 2019 Sep 6.
- Starnes K, Miller K, Wong-Kisiel L, Lundstrom BN. A Review of Neurostimulation for Epilepsy in Pediatrics. Brain Sci. 2019 Oct 18;9(10):283. doi: 10.3390/brainsci9100283.
- Alcala-Zermeno JL, Gregg NM, Van Gompel JJ, Stead M, Worrell GA, Lundstrom BN. Cortical and thalamic electrode implant followed by temporary continuous subthreshold stimulation yields long-term seizure freedom: A case report. Epilepsy Behav Rep. 2020 Sep 2;14:100390. doi: 10.1016/j.ebr.2020.100390. eCollection 2020.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- CAD2004
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .